Angiogenesis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enzon Pharmaceuticals, Inc.
Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
June 19th, 2009
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that data from the Company’s HIF-1 alpha Phase 1 study evaluating EZN-2968 in patients with solid tumors and lymphoma was presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida. Study data demonstrated that the compound is well tolerated, and that early signs of clinical benefit, prolonged stable disease, were observed in several patients. EZN-2968 is the first clinical product candidate to target the HIF-1 transcription factor. HIF-1 regulates expression of many key genes important in cancer biology. The poster can be found in the Research and Development section of the Company’s web site...
Source: Angiogenesis Weekly (2009-06-19)
|
